Tovinontrine
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Tovinontrine
- Molecular weight
- 394.48
- Structure (SMILES)
- C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(C3CCOCC3)ncc2c(=O)[nH]1
- 68722
- af 68722
- AF-68722
- af68722
- AF68722
- ck 1598
- CK-1598
- ck1598
- CK1598
- imr 687
- Imr-687
- IMR-687
- tovinontrina
- Tovinontrina
- TOVINONTRINA
- tovinontrine
- Tovinontrine
- TOVINONTRINE
- Tovinontrine (CRD-750
- Tovinontrine (CRD-750)
- tovinontrine [INN]
- TOVINONTRINE [USAN]
- Tovinontrine [WHO-DD]
- tovinontrine inn
- tovinontrine usan
And 1 more, listed on the interactive page.
- CAS registry numbers
- 2062661-53-2
- ChEMBL ID
- CHEMBL4297290
- InChIKey
- GWGNPYYVGANHRJ-GDBMZVCRSA-N
- PubChem compound IDs
- 124220601
- FDA ingredient codes (UNII)
- W248Y1AKOR
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -nontrine; -vin-
Mechanisms of action
- Mechanism
- Phosphodiesterase 9A inhibitor
- Action type
- Inhibitor
- Target
- High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
- Protein identifier
- O76083
Open Targets mechanisms
- Mechanism
- Phosphodiesterase 9A inhibitor
- Action type
- Inhibitor
- Target
- High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
- Condition
- Heart Failure
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Anemia, Sickle Cell
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0011382
- Subject identifier
- D000755
- Condition
- beta-Thalassemia
- Highest recorded phase
- 2
- Condition identifier
- Orphanet:848
- Subject identifier
- D017086
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011382
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019402
- Highest recorded phase
- 2
- Condition identifier
- Orphanet_848
- Highest recorded phase
- 2
- NCT02998450
- NCT03401112
- NCT04053803
- NCT04474314
- NCT04411082
- NCT05312021
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 88.41
- Calculated partition coefficient (ALogP)
- 1.94
- Calculated partition coefficient (XLogP)
- 0.4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 29
- Molecular formula
- C21H26N6O2
- Monoisotopic mass
- 394.21172409
- Natural product
- No
- Recorded assays
- 9
- Active assays
- 9
Active assay types
- Confirmatory
Related records
Trials (8)
- A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
- A Study of IMR-687 in Healthy Adult Volunteers
- A Study of IMR-687 in Subjects With Beta Thalassemia
- A Study of IMR-687 in Subjects With Sickle Cell Disease
- A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
- An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
- Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
- Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
In development for (3)
- Beta thalassemia Phase 2
- Heart failure Phase 2
- Sickle cell disease Phase 2
Targets (1)
- PDE9A Phosphodiesterase 9A inhibitor